Cardiovascular · AntiplateletRegulatory Approvalregulatorymid-term

Hikma's Dipyidamole ANDA074521 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma20 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 12:33:11 AM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's receipt of Abbreviated Approval (AP) for Dipyidamole positions the company favorably within the competitive landscape of cardiovascular generics. This regulatory milestone necessitates close monitoring of market dynamics and potential impacts on pricing and market share. Regulatory context from FDA (FDA AP — DIPYRIDAMOLE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies in the cardiovascular space. The strongest clinical anchor is Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (ClinicalTrials.gov), sponsor/company relevance (lilly). In Cardiovascular · Antiplatelet, 8 regulatory and 3 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis. This approval may enhance Hikma's position in the cardiovascular market, particularly in the generic segment for antiplatelet therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIPYRIDAMOLE (SUPPL) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The AP status indicates a streamlined pathway for Hikma's product, which could influence future regulatory submissions and approvals in the cardiovascular space.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)) could weigh on Hikma through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatia) could weigh on Hikma through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Remote Monitoring and Optimization of Heart Failure Therapy) could weigh on Hikma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval may lead to increased market share for Hikma in the generic antiplatelet segment, potentially affecting pricing strategies and competitive positioning against other generics.
Portfolio teams should assess the impact of this approval on market share and pricing strategies in the cardiovascular space.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential market entry of competing generics.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIPYRIDAMOLE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PARICALCITOL (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROXICET (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Nutritional Screening in Cardiovascular Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
RSV Immunisation Status in Queensland (Australia)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Metformin to Improve Cardiac Function After LVAD Implantation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Remote Monitoring and Optimization of Heart Failure Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source

Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Dipyidamole

Commercial impact

medium

The approval may lead to increased market share for Hikma in the generic antiplatelet segment, potentially affecting pricing strategies and competitive positioning against other generics.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Hikma's product, which could influence future regulatory submissions and approvals in the cardiovascular space.

What to watch

Monitor for the launch timeline and any potential market entry of competing generics.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.